Protia Inc. (KOSDAQ:303360)
South Korea · Delayed Price · Currency is KRW 5,250.00
+70.00 (1.35%)
At close: Sep 11, 2026
Protia Revenue
Protia had revenue of 5.35B KRW in the quarter ending June 30, 2026, with 39.08% growth. This brings the company's revenue in the last twelve months to 17.75B, up 42.75% year-over-year. In the year 2025, Protia had annual revenue of 15.12B with 43.80% growth.
Revenue (ttm)
17.75B
Revenue Growth
+42.75%
P/S Ratio
3.81
Revenue / Employee
n/a
Employees
n/a
Market Cap
67.62B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.12B | 4.61B | 43.80% |
| Dec 31, 2024 | 10.51B | 2.29B | 27.79% |
| Dec 31, 2023 | 8.23B | 583.85M | 7.64% |
| Dec 31, 2022 | 7.64B | 4.09B | 115.34% |
| Dec 31, 2016 | 3.55B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Medical Science | 102.16B |
| Seoulin Bioscience | 83.17B |
| Cytogen | 27.38B |
| Dx & Vx | 26.22B |
| HLB Panagene | 14.71B |
| 3billion | 11.71B |
| GENINUS | 11.28B |
| Median Diagnostics | 7.86B |